U.S. Markets close in 1 min
  • S&P 500

    -4.74 (-0.13%)
  • Dow 30

    -165.15 (-0.55%)
  • Nasdaq

    +58.74 (+0.49%)
  • Russell 2000

    -8.48 (-0.46%)
  • Crude Oil

    +0.81 (+1.80%)
  • Gold

    +0.60 (+0.03%)
  • Silver

    +0.07 (+0.30%)

    +0.0031 (+0.2624%)
  • 10-Yr Bond

    -0.0040 (-0.45%)
  • Vix

    -0.47 (-2.17%)

    +0.0033 (+0.2491%)

    -0.0700 (-0.0670%)

    -206.60 (-1.09%)
  • CMC Crypto 200

    +1.35 (+0.36%)
  • FTSE 100

    -41.08 (-0.64%)
  • Nikkei 225

    +131.27 (+0.50%)

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ODT, NXTC and MESO

·3 min read

NEW YORK, NY / ACCESSWIRE / November 13, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Odonate Therapeutics, Inc. (NASDAQ:ODT)
Class Period: December 7, 2017 - April 21, 2020
Lead Plaintiff Deadline: November 16, 2020

The complaint alleges that throughout the class period Odonate Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's orally administered chemotherapy agent, tesetaxel, was not as safe or well-tolerated as the Company had led investors to believe; (ii) consequently, tesetaxel's commercial viability as a cancer treatment was overstated; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in ODT: http://www.kleinstocklaw.com/pslra-1/odonate-therapeutics-inc-loss-submission-form?id=10936&from=1

Nextcure, Inc. (NASDAQ:NXTC)
The Nextcure lawsuit was filed on behalf of investors who purchased Nextcure, Inc. (NASDAQ: NXTC) securities: (1) between November 5, 2019 and July 14, 2020, inclusive; and/or (2) pursuant or traceable to the company's secondary public offering declared effective on November 14, 2019.
Lead Plaintiff Deadline: November 20, 2020

Throughout the class period defendants' statements were materially misleading because the data Defendants possessed on its principle product candidate, NC318, showed a lack of efficacy and objective responses. Had the truth been revealed, the market would have seen that NC318 was not, in fact, effective in treating most tumor types, that the NC318 application was proving to be limited (if even useful at all), and, as a result, there was a significant realizable risk that NC318 would not be nearly as popular as then-existing blockbuster drugs, such as Keytruda.

Learn about your recoverable losses in NXTC: http://www.kleinstocklaw.com/pslra-1/nextcure-inc-loss-submission-form?id=10936&from=1

Mesoblast Limited (NASDAQ:MESO)
Class Period: April 16, 2019 - October 1, 2020
Lead Plaintiff Deadline: December 7, 2020

The complaint alleges that during the class period Mesoblast Limited made materially false and/or misleading statements and/or failed to disclose that: (1) comparative analyses between Mesoblast's Phase 3 trial and three historical studies did not support the effectiveness of the Company's lead product candidate, remestemcel-L, for steroid refractory acute graft versus host disease due to design differences between the four studies; (2) as a result, the US Food and Drug Administration was reasonably likely to require further clinical studies; (3) as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in MESO: http://www.kleinstocklaw.com/pslra-1/mesoblast-limited-loss-submission-form?id=10936&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665

SOURCE: The Klein Law Firm

View source version on accesswire.com: